Versant Venture Management’s Century Therapeutics IPSC Stock Holding History

Versant Venture Management’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.8M	Hold	12,166,109	–	–	18.33%	2
2026 Q1	$27.5M	Buy	+12,166,109	New	+$25.6M	19.44%	2

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Versant Venture Management's IPSC Position: Q2 2026 in Review

Versant Venture Management held its Century Therapeutics (IPSC) position steady in Q2 2026 at 12,166,109 shares worth $29.8M. The position accounts for 18.33% of the portfolio, ranked #2.

Versant Venture Management first reported a position in IPSC in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

Versant Venture Management held 12,166,109 shares of Century Therapeutics worth $29.8M as of Q2 2026.
Versant Venture Management left its Century Therapeutics share count unchanged in Q2 2026.
Century Therapeutics made up 18.33% of Versant Venture Management's portfolio in Q2 2026, its #2 holding.
Versant Venture Management first reported a position in Century Therapeutics in Q1 2026 and has held it in 2 quarters since.
100 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Versant Venture Management's 13F filing for Q2 2026, filed 12 Aug 2026.